Πέμπτη 7 Σεπτεμβρίου 2017

Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest

The phase III trial of Liang et al. [1] on the optimal chemotherapy regimen for concurrent chemoradiation in patients with inoperable stage III NSCLC is of interest as it contradicts, in part, previously published data. Surprisingly, the study revealed a survival advantage for etoposide/cisplatin (EP) (administered every 4 weeks) over paclitaxel/carboplatin (PC) weekly concurrent chemoradiation and did not confirm results from the previous Veterans Affairs Central Cancer Registry analysis [2]. Despite a relatively high rate of stage IIIB disease and low rate of complete remission, favorable 2- and 3-year overall survival was achieved.

http://ift.tt/2wcZcMf

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου